{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"88"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"108"}],"title":"No"}],"title":"Bisphosphonates"},{"categories":[{"measurements":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"113"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"83"}],"title":"No"}],"title":"Corticosteroids"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"192"}],"title":"No"}],"title":"Antifungals"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"194"}],"title":"No"}],"title":"Erythropoietin Stimulating Agents"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"193"}],"title":"No"}],"title":"Granulocyte macrophage colony-stimulating factor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"115"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"81"}],"title":"No"}],"title":"Novel Androgen Axis Drugs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"45"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"151"}],"title":"No"}],"title":"Antiemetics"},{"categories":[{"measurements":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"96"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"100"}],"title":"No"}],"title":"Opioid analgesics"}],"denoms":[{"counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"description":"The list of concomitant drugs as captured on the concomitant medication/therapy CRF page to include in each category was pre-specified and flagged prior to the pre planned analyses. (1) Bisphosphonates (including but not limited to zoledronic acid, alendronic acid, etc.), denosumab, and other bone targeted therapies), (2) Corticosteroids for systemic use (3), Antifungals for systemic use (i.e. ketoconazole), (4) ESA (erythropoietin stimulating agents, i.e. epoetin alfa), (5) Granulocyte macrophage colony-stimulating factor (GM-CSF), (6) Novel androgen axis drugs (NAADs; i.e. enzalutamide, abiraterone, apalutamide), (7) Antiemetics and (8) Opioid analgesics use for cancer-related pain.","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"PFS Full Analysis Set (PFS-FAS)","reportingStatus":"POSTED","timeFrame":"From date of randomization till 30 days safety fup, assessed up to approximately 32 months (Primary Analysis cut-off date = 27-Jan-2021)","title":"Concomitant Drug Use for Health Economics Analysis","type":"SECONDARY","unitOfMeasure":"Participants"}